219
Participants
Start Date
June 5, 2013
Primary Completion Date
September 16, 2020
Study Completion Date
September 16, 2020
Regorafenib
Regorafenib (160 mg/d) once daily for three weeks on / one week off plus Best Supportive Care (BSC)until progression (according to RECIST 1.1), intolerance or consent withdrawal.
Placebo
Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression
AKH-Wien, Vienna
Krankenhaus der Barmherzigen Schwestern Linz, Linz
Universitätsklinik für Innere Medizin I, Innsbruck
Medizinische Universität Graz, Graz
Institut Paoli Calmettes, Marseille
Hôpital de La Timone, Marseille
Centre François Baclesse, Caen
Centre GF Leclercq, Dijon
Hôpital St Jacques, Besançon
Institut Claudius Regaud, Toulouse
Institut Bergonié, Bordeaux
Centre Eugène Marquis, Rennes
Institut de Cancérologie Lucien Neuwirth (ICL), Saint-Priest-en-Jarez
Centre René Gauducheau, Nantes
Centre Alexis Vautrin, Vandœuvre-lès-Nancy
Centre Oscar Lambret, Lille
Centre Léon Bérard, Lyon
Institut Curie, Paris
Hôpital Saint Louis, Paris
Hôpital Cochin, Paris
Centre Henri Becquerel, Rouen
Institut Curie - Hôpital René Huguenin, Saint-Cloud
Institut Gustave Roussy, Villejuif
LKH, Klagenfurt
Centre Antoine Lacassagne, Nice
Collaborators (1)
Bayer
INDUSTRY
Centre Oscar Lambret
OTHER